Evidence map›Paper›PMID 35000531›Full record

ArticleBioengineered2022

Long non-coding RNA CCL2 promoted gastric cancer function via miR-128/ PARP2 signal pathway.

Liang Ma, Yunshan Jiang, Ning Wu

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Network pharmacology study andWorld journal of gastrointestinal oncology · 2024
    Article
  3. Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal transduction and targeted therapy · 2024
    Review
  4. Review
  5. MicroRNA-128 acts as a suppressor in the progression of gastrointestinal stromal tumor by targeting B-lymphoma Mo-MLV insertion region 1.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Liang MaDepartment of Digestive Internal Medicine,Shaoxing No. 2 Hospital Medical Community General Hospital,Shaoxing, Zhejiang Province, China.
Yunshan JiangDepartment of Oncology, Longyan First Hospital, Affiliated to Fujian Medical University,Longyan, P.R. China.
Ning WuDepartment of Oncology, Shanghai Pudong New Area Gongli Hospital, Shanghai, P.R. China.
Fujian Medical University · CNShanghai Pudong New Area Gongli Hospital · CNShaoxing No.6 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amounts of studies have revealed long non-coding RNA (lncRNA) was related to the development of gastric cancer. Here, our results suggested the function and regulatory mechanism of CCL2 in gastric cancer. Quantitative polymerase-chain reaction (qPCR) was employed to inspect lncRNA CCL2 and miR-128 expression in normal gastric cell line (GES-1) and tumor cell lines (HGC-27 and MKN-45). The effects of CCL2 and miR-128 were measured via Luciferase reporter test. Western blot was used to check PARP2 protein expression. CCL2 expression and PARP2 protein levels were up-regulated, while miR-128 expression was obviously lower. Meanwhile, CCL2 down-regulating significantly repressed the proliferation, migration, and invasion by regulating miR-128. In addition, we proved miR-128 was a direct target of CCL2 through double luciferase assay and bioinformatics analysis. Moreover, miR-128 markedly inhibited the proliferation, migration, and invasion in gastric cancer. More importantly, miR-128 could reverse the effects of lncRNA CCL2 knocked down. PARP2-si obviously suppressed in gastric cancer proliferation, migration, and invasion. Meanwhile, miR-128 mimic and the knockout of CCL2 distinctly decreased PARP2 protein level. Additionally, luciferase report experiments certificated that PARP2 targeted miR-128, implying PARP2 directly interacted with miR-128 in gastric cancer. More interestingly, the downregulation of PARP could reverse the trend triggered by miR-128 inhibitor in gastric tumor. All over these results showed lncRNA CCL2 played importance of role in gastric tumor via miR-128/PARP2 axis signal pathway. LncRNA CCL2 accelerated gastric cancer progression by regulating miR-128/PARP2 signaling pathway, providing a novel possible strategy for the treatment of gastric cancer.

Indexed as

Cell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticGene Knockout TechniquesHumansMicroRNAsPoly(ADP-ribose) PolymerasesRNA, Long NoncodingSignal TransductionStomach NeoplasmsUp-RegulationMicroRNAsMIRN128 microRNA, humanPARP2 protein, humanPoly(ADP-ribose) PolymerasesRNA, Long NoncodingCCL2Gastric cancerinvasionmigrationmiR-128PARP2proliferation

Identifiers

PMID35000531
PMCPMC8805977
OpenAlexW4206174599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.